BFS
OLMA icon

Bare Financial Services’s Olema Pharmaceuticals OLMA Stock Holding History

Bare Financial Services’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$298 – 1877
2026
Q1 		$298 Buy
+20
New +$445 ﹤0.01% 1710

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Bare Financial Services's OLMA Position: Q2 2026 in Review

Bare Financial Services sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 20 shares — an estimated $298 sold.

Bare Financial Services first reported a position in OLMA in Q1 2026 and held it in 1 quarter. The position peaked at $298 in Q1 2026. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Bare Financial Services reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bare Financial Services sold 20 Olema Pharmaceuticals shares in Q2 2026, an estimated $298.
  • Bare Financial Services first reported a position in Olema Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Bare Financial Services's Olema Pharmaceuticals position peaked at $298 in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.